Company Overview
Drive AI healthcare evolution through M&A integration
Accelerate inclusive innovation via ecosystem synergy
We believe the most efficient business aligns with the deepest social good
ETHK Labs: From life-science guardian to future health architect
The ETHK Labs story (01931.HK) began with decades of commitment to China’s healthcare system. Our subsidiary Wisd has been the exclusive distributor of Sysmex coagulation products in China since 1997, supplying reliable diagnostics to thousands of medical institutions. We have installed over 6,600 coagulation analyzers, built a nationwide network across 31 provinces, and reached 1,711 tertiary hospitals. This multi-decade dedication anchors us in real clinical needs.
Yet our lens has always been the future. With the global wave of AI reshaping healthcare and national strategies such as ‘AI+’ and ‘Healthy China 2030’, ETHK Labs completed a strategic elevation. In 2025 we rebranded as ETHK Labs Inc. and strategically acquired Bsoft (300451.SZ), marking our shift from an excellent medical device operator to a leading AI healthcare capital operations platform.
‘ETHK’ stands for the fusion of Ether and Knowledge — a bridge between global medical intelligence and scaled real-world application. Our strategy is rooted in the belief that high‑tech life‑science IP (‘K’) creates enduring value, powered by advanced AI algorithms (‘A’).
Leveraging dual listings in Hong Kong and the Nasdaq (in progress), we systematically seek and integrate AI healthcare leaders that meet the ‘High‑Tech, Global, Large‑Asset’ standard. Post‑acquisition is where value creation begins: our three-curve system injects growth, optimizes operations, and compounds value through diverse capital pathways.
Each acquisition is driven by an altruistic mission. We believe sustainable success happens only when every stakeholder—portfolio companies, medical institutions, clinicians, patients, and investors—shares in real growth and benefit. That conviction guides us toward a more efficient, equitable, and accessible global healthcare future.
M&A Business + Three Curves (K1-K2-K3)
M&A Business: Building the AI Healthcare Core Ecosystem
We precisely target global AI healthcare category leaders and build an industry‑wide synergy ecosystem. In an era of national ‘AI+’ initiatives and emerging-industry policies, our M&A strategy is the core lever to build long‑term competitiveness.
Three Curves: ETHK Labs’ unique empowerment engine
Derived from Charles Handy’s ‘Second Curve’ theory: any organization follows an S‑curve from growth to decline, so new growth curves must start before the first peaks. This framework has evolved into a three‑curve strategy—representing today’s core business, the next growth engine, and the future industrial paradigm.
K1: IVD Distribution Network
A solid foundation for innovation deployment
We operate a nationwide distribution network across 31 provinces, directly serving 236 institutions and reaching 1,711 tertiary hospitals through 1,073 distributors. This curve provides immediate market entry for acquired AI healthcare companies and enables rapid integration of diagnostics, devices, and clinical scenarios.
• Represents the organization’s core business and existing growth model.
K2: HuaJian Ecosystem
A hub for collaborative innovation
A global value‑aggregation platform for IVD and AI healthcare IP, and a collaborative community for member growth. We break technical barriers and enable co‑creation across innovators, medical institutions, and research partners.
• Represents the innovation path opened before Curve 1 peaks.
K3: Capital Operations (IP Securitization)
An efficient channel for value realization
We transform acquired core patents, AI algorithms, and mature healthcare technologies into liquid financial products through professional valuation and compliant structures—realizing IP value at scale.
• Represents the future paradigm beyond business growth—ecosystem and social value creation.
The three curves work in synergy, building momentum layer by layer, empowering acquired assets and forming a sustainable industry value ecosystem.
Strategic Core Values
Accelerate Therapy Access
Shorten the long journey from lab breakthroughs to bedside care through innovative capital models.
Empower Innovation Engines
Remove funding barriers so global scientists and R&D teams can focus on life‑changing discoveries.
Build Healthcare Foundations
Use nationwide diagnostic networks to deliver earlier, more accurate screening to billions.
“We believe the greatest innovations begin with deep patient insight. ETHK Labs’ mission is to unlock the value of every piece of intellectual property through capital, accelerating therapies that benefit the world.
”— Executive Team